Sanofi-Aventis (NYSE: SNY) unveiled a further push into emerging markets with plans to buy Polish consumer healthcare group Nepentes in a deal valuing it at around 105 million euros ($130.4 million). Release | Report
FiercePharma is the pharma industry's daily monitor, with a special focus on pharmaceutical company news and the market development of FDA approved products. Join 100,000+ pharma industry leaders who get FiercePharma via daily email. Click here to get your free weekly email briefing today!